Envafolimab plus chemoradiation and endostatin for advanced nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of a new immunotherapy (envafolimab) with standard chemoradiation and a drug that blocks blood vessel growth (endostatin) for people with advanced nasopharyngeal cancer that hasn't been treated before. The goal is to see if this combination works better than the usual treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- Your cancer is locally advanced (stage III or IVA) and has not spread to other parts of the body.
- You have not had any prior radiation or chemotherapy for this cancer.
- You are able to do most daily activities without help (ECOG 0-1).
- You are willing to provide a tumor tissue sample and have blood tests for PD-L1 and EBV.
- You are not pregnant or breastfeeding, and you do not have active hepatitis B or C, HIV, or other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding endostatin and capecitabine to standard radiation can improve outcomes for people with non-keratinizing nasopharyngeal cancer that has not responded well to chemotherapy. It may help those with stable or worsening disease after treatment before moving to radiation.
This trial tests a combination of chemotherapy (three drugs: docetaxel, cisplatin, and fluorouracil) plus an immunotherapy drug (a PD-1 inhibitor, which helps your immune system fight cancer) given before the standard radiation treatment for nasopharyngeal cancer. The goal is to see if this upfront treatment can improve outcomes in patients whose cancer has not spread to distant parts of the body.
This Phase 3 trial tests a stronger treatment approach for people with locally advanced nasopharyngeal cancer whose EBV “DNA” (a cancer-related virus signal in blood) does not go away after one cycle of chemotherapy. It may help improve outcomes by changing treatment based on how the cancer responds early.
This trial tests a new combination of immunotherapy (JS001) and chemotherapy (PFLL) versus a standard regimen (GP) for people with nasopharyngeal cancer that has spread. The goal is to see if the new combination works better at controlling the disease.
This trial studies whether adding envafolimab (an immune medicine) to standard chemo and radiation works better for people with locally advanced, untreated nasopharyngeal cancer. It may help the immune system attack the cancer while treatment shrinks it.
This trial tests a new treatment plan for nasopharyngeal cancer that avoids platinum-based chemotherapy, which can have harsh side effects. It may help patients with stage II or III disease by using other drugs to control the cancer.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.